Oxford BioDynamics - PDMR Dealing
("OBD" or the "Company" and, together with its subsidiaries, the "Group")
PDMR Dealing
Following this transaction,
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details:
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
|||||
|
a) |
|
|
||||
|
2 |
Reason for the notification |
|||||
|
a) |
Position/status |
Director/PDMR |
||||
|
b) |
Initial notification/ Amendment |
Initial notification |
||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
|
|
||||
|
b) |
LEI |
2138005Y1TK258O5U928 |
||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary Shares of
ISIN: GB00BD5H8572 |
||||
|
b) |
Nature of the transaction |
Acquisition of ordinary shares |
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information - Aggregated volume - Price
|
|
||||
|
e) |
Date of the transaction |
|
||||
|
f) |
Place of the transaction |
Outside a trading venue |
||||
For further details please contact:
|
|
+44 (0)1865 518910 |
|
Shore Capital Nominated Adviser and Broker
|
+44 (0)20 7408 4090 |
|
FTI Consulting Financial Public Relations Adviser
|
+44 (0)20 3727 1000 |
Notes for Editors
About
The Company's award-winning, proprietary technology platform, EpiSwitch™, offers non-invasive liquid biopsy readouts to the standards of validated predictive, prognostic and diagnostic patient stratifications, and aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.
In particular, EpiSwitch™ offers non-invasive molecular read-outs with strong links to clinical outcomes, and helps reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.
In
The Company is headquartered in the
This information is provided by RNS, the news service of the
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE